Selank: a Russian research compound with anxiolytic history
A peptide with a real clinical record — just not one built within the FDA regulatory framework.
TL;DR
- Selank is a synthetic heptapeptide analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences.
- Russian clinical studies have investigated selank for generalized anxiety; it is registered as a pharmaceutical in Russia but has not undergone FDA evaluation.
- As of publication, selank is classified as Category 2 and is not available from 503A compounding pharmacies in the United States.
What it is
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a seven-amino-acid peptide created by appending a tripeptide stabilizing sequence (Pro-Gly-Pro) to the four-amino-acid sequence of tuftsin, an endogenous peptide produced by the spleen. Tuftsin has immunomodulatory properties; selank was designed to extend its stability and add anxiolytic effects. It is administered intranasally — the peptide is too hydrophilic for significant oral bioavailability and too large for straightforward subcutaneous delivery at the doses used in research. In Russia, it has been approved as a pharmaceutical since 2009 under the name "Selank" for anxiety-related indications.
How it works
Selank's mechanism is not fully characterized. Proposed effects include modulation of the GABAergic system (the pathway through which most benzodiazepines act), influence on serotonin transporter expression, and effects on brain-derived neurotrophic factor (BDNF) — a protein involved in neuronal health and plasticity. Animal studies have shown anxiolytic effects in rodent models without the sedation or dependence concerns associated with classical benzodiazepines. Whether these mechanisms translate cleanly to humans at clinically meaningful doses via intranasal administration has not been established through FDA-independent trials.
Who asks about it
Selank comes up in conversations about cognitive performance and anxiety management, often from people who are frustrated with conventional anxiolytics and looking for alternatives with different side-effect profiles. It also appears in discussions about peptide-based nootropics. The appeal is understandable — anxiety and cognitive performance are genuine quality-of-life concerns for many people in midlife.
What the research says
A clinical trial published in Bulletin of Experimental Biology and Medicine (Semenova et al., 2010) evaluated selank in patients with generalized anxiety disorder and neurasthenia. Participants receiving selank showed improvement on anxiety rating scales compared to baseline, and the authors reported a favorable tolerability profile. However, this trial was conducted in Russia with a study population and methodology that has not been independently replicated in Western clinical settings. A search of ClinicalTrials.gov finds no completed or active US trials for selank as of this writing. The Russian literature is real; independent external validation remains absent.
What to know before considering it
The regulatory position is definitive for now: selank is Category 2 in the US and is not available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning certain Category 2 peptides — including selank — to Category 1 pending formal Federal Register rulemaking, but that process is not final. Even if reclassification occurs, intranasal peptide delivery introduces its own pharmacokinetic variables that require careful clinical evaluation.
The Halftime POV
Selank represents a category of compounds that have genuine clinical histories in one regulatory context and essentially no formal history in another. That gap — between Russian pharmaceutical approval and FDA evaluation — is significant, and it's not one that anecdote can bridge. The underlying question it raises, around non-sedating anxiolysis, is worth taking seriously. The path to answering it reliably runs through independent clinical trials.
Related reading:
FAQ
Q: What is Selank? A: Selank is a synthetic heptapeptide analog of tuftsin — a naturally occurring immunomodulatory tetrapeptide. It was developed in Russia and has been used clinically there for anxiety and cognitive enhancement. It is not FDA-evaluated and as of April 2026 is Category 2 in the US, not available through 503A compounding pharmacies.
Q: What does the published research show about Selank? A: Published Russian clinical literature describes anxiolytic effects in patients with generalized anxiety disorder, with some studies comparing it favorably to benzodiazepines for certain endpoints. These studies were conducted in Russia and are not replicated in US FDA-standard randomized controlled trials. The evidence base is real but geographically concentrated and not FDA-reviewed.
Q: Is Selank available in the United States? A: No. Selank is Category 2 under FDA's 503A bulk drug substance framework as of April 2026. It cannot be legally dispensed by US compounding pharmacies. Any source claiming to provide Selank through a 503A pharmacy in the US as of April 2026 is making a claim that warrants verification.
Disclaimer
As of April 2026, selank is classified by the FDA as Category 2, which means it is not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- Semenova TP et al. "Selank and its component peptides affect anxiety and serotonin metabolism in the brain." — Bull Exp Biol Med, 2010
- Uchakina ON et al. "Immunomodulatory effects of selank in patients with anxiety-asthenic disorders." — Zh Nevrol Psikhiatr Im S S Korsakova, 2008
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is Selank?
Selank is a synthetic heptapeptide analog of tuftsin — a naturally occurring immunomodulatory tetrapeptide. It was developed in Russia and has been used clinically there for anxiety and cognitive enhancement. It is not FDA-evaluated and as of April 2026 is Category 2 in the US, not available through 503A compounding pharmacies.
What does the published research show about Selank?
Published Russian clinical literature describes anxiolytic effects in patients with generalized anxiety disorder, with some studies comparing it favorably to benzodiazepines for certain endpoints. These studies were conducted in Russia and are not replicated in US FDA-standard randomized controlled trials. The evidence base is real but geographically concentrated and not FDA-reviewed.
Is Selank available in the United States?
No. Selank is Category 2 under FDA's 503A bulk drug substance framework as of April 2026. It cannot be legally dispensed by US compounding pharmacies. Any source claiming to provide Selank through a 503A pharmacy in the US as of April 2026 is making a claim that warrants verification.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.